Media

Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLD Symposium

Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Vicore Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference

Oncopeptides – Research shows that Pepaxti is effective in high-risk myeloma

Gesynta Pharma forms Scientific Advisory Board with international endometriosis experts

Vicore Pharma to move to the Nasdaq Stockholm Mid Cap segment

Clinical studies with Strangvac have begun in the U.S. market

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors